Ascletis Pharma Stock Profit Margin
ASCLF Stock | USD 1.04 0.12 13.04% |
Ascletis Pharma fundamentals help investors to digest information that contributes to Ascletis Pharma's financial success or failures. It also enables traders to predict the movement of Ascletis Pink Sheet. The fundamental analysis module provides a way to measure Ascletis Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ascletis Pharma pink sheet.
Ascletis |
Ascletis Pharma Company Profit Margin Analysis
Ascletis Pharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Ascletis Pharma Profit Margin | (2.24) % |
Most of Ascletis Pharma's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ascletis Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition |
Based on the latest financial disclosure, Ascletis Pharma has a Profit Margin of -2.2431%. This is 79.99% lower than that of the Healthcare sector and 90.26% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 76.62% higher than that of the company.
Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
All Next | Launch Module |
Ascletis Fundamentals
Return On Equity | -0.0632 | |||
Return On Asset | -0.053 | |||
Profit Margin | (2.24) % | |||
Operating Margin | (3.11) % | |||
Current Valuation | 116.15 M | |||
Shares Outstanding | 1.09 B | |||
Shares Owned By Insiders | 67.02 % | |||
Shares Owned By Institutions | 1.94 % | |||
Price To Book | 1.58 X | |||
Price To Sales | 7.61 X | |||
Revenue | 76.88 M | |||
Gross Profit | 39.17 M | |||
EBITDA | (169.35 M) | |||
Net Income | (199.02 M) | |||
Cash And Equivalents | 2.5 B | |||
Cash Per Share | 2.28 X | |||
Total Debt | 2.75 M | |||
Debt To Equity | 0 % | |||
Current Ratio | 28.93 X | |||
Book Value Per Share | 2.50 X | |||
Cash Flow From Operations | (146.93 M) | |||
Earnings Per Share | (0.03) X | |||
Number Of Employees | 315 | |||
Beta | 0.81 | |||
Market Capitalization | 672.93 M | |||
Total Asset | 2.83 B | |||
Net Asset | 2.83 B |
About Ascletis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascletis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascletis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascletis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.